PMID: 7537394Apr 27, 1995Paper

Anti-CD2 monoclonal antibody-induced receptor changes: down modulation of cell surface CD2

Transplantation
J LinJ S Bromberg

Abstract

Anti-CD2 mAbs suppress T cell immunity and prolong allograft survival in vivo while inducing the down-modulation of CD2 expression. Manipulation of cell surface molecules may be important in inducing tolerance, so down-modulation of CD2 expression on T cells by anti-CD2 mAbs was further defined with an in vitro model. The anti-CD2 mAb 12-15 caused CD2 expression on purified splenic T cells to decrease from 83.4 to 22.7% total positive cells while CD3, CD4, and CD8 expression remained unchanged. The expression of other adhesion molecules, LFA-1 alpha (CD11a), LFA-1 beta (CD18), Pgp-1 (CD44), CD45, MEL-14 (L-selectin), and VLA-4 alpha (CD49d), were all increased as a result of anti-CD2 treatment, whereas CD25 (IL-2R), CD48 (CD2 ligand), and ICAM-1 (CD54) remained unchanged. Kinetics showed that CD2 down-modulation was persistent and at the same magnitude from day 1 through day 7 of culture. Anti-CD2 mAb could down modulate CD2 on both CD4 and CD8 splenic lymphocyte subsets, thymocytes, and the T cell lymphoma EL-4; and, non-T cells did not seem to participate in the process of modulation. Mechanistic studies of mAb action showed that, in addition to 12-15, other anti-CD2 mAbs could cause down-modulation of T cell CD2 expression i...Continue Reading

Citations

Mar 1, 1996·Transplant Immunology·G AndresD Stern
Mar 30, 1999·Transplantation·J D PunchJ S Bromberg
Jun 1, 2005·Laboratory Investigation; a Journal of Technical Methods and Pathology·Nina N PawlowskiJörg C Hoffmann
Sep 29, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·L C TajraJ P Revillard

❮ Previous
Next ❯

Related Concepts

Related Feeds